Search Results

You are looking at 1 - 10 of 11 items for :

  • DPP4 inhibitors x
Clear All
Open access

E Rapti, S Karras, M Grammatiki, A Mousiolis, X Tsekmekidou, E Potolidis, P Zebekakis, M Daniilidis and K Kotsa

-glutamic acid decarboxylase antibodies (GAD-abs), which were normalized after combined treatment with a dipeptidyl peptidase-4 inhibitor (DPP-4) inhibitor (sitagliptin) and cholecalciferol. Case presentation A 31-year-old Caucasian male was referred to

Open access

Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro and Margareth Afonso Torres

uncommon. In general terms, partial remission is defined as a daily requirement of insulin <0.5 IU/kg and levels of HbA1c <6% and stimulated C-peptide >0.90 ng/mL ( 4 , 5 ). Dipeptidyl peptidase 4 (DPP-4) inhibitors, such as sitagliptin, have been used

Open access

Marcos M Lima-Martínez, Ernesto Guerra-Alcalá, Miguel Contreras, José Nastasi, Janelle A Noble and Constantin Polychronakos

demonstrated that inhibitors of dipeptidyl peptidase 4 (DPP4) can diminish daily insulin requirements and improve metabolic control without exacerbating the risk of hypoglycemia in T1DM patients (7) (8) . However, as far as we are concerned, there has been

Open access

Murray B Gordon and Kellie L Spiller

optimal first-line antidiabetic medication ( 12 ). Metformin-based antidiabetic therapy can be intensified with the addition of a dipeptidyl peptidase-4 (DPP-4) inhibitor, such as sitagliptin. If necessary to achieve optimal glycemic control, the DPP-4

Open access

Jiman Kim, Eulsun Moon and Seungwon Kwon

, is long-standing hypertensive diabetes mellitus, characterized pathophysiologically by glomerular hyperfiltration. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), both commonly used in preventing diabetic

Open access

Michelle Maher, Mohammed Faraz Rafey, Helena Griffin, Katie Cunningham and Francis M Finucane

). Commercial meal replacement programmes have recently shown promise in managing T2DM ( 4 ), but side effects including constipation, dizziness, alopecia, nausea, headache, diarrhoea, abdominal pain and cholelithiasis are common ( 5 ), and these interventions

Open access

Senhong Lee, Aparna Morgan, Sonali Shah and Peter R Ebeling

. Frontiers in Endocrinology 2013 4 1 – 12 . ( ) 7 Fralick M Scheeweiss S Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor . New England Journal of Medicine 376 2300

Open access

Rajesh Rajendran, Sarita Naik, Derek D Sandeman and Azraai B Nasruddin

literature search revealed 15 possible cases of pituitary adenomas secreting both ACTH and GH (2) (3) (4) (5) (6) (7) (8) . This cannot be confirmed in five of these cases, due to unavailability of modern immunohistochemistry techniques (2) (3

Open access

Elena Carrillo, Amparo Lomas, Pedro J Pinés and Cristina Lamas

bilateral renal cyst and pelvic ecstasy are observed. Table 1 Initial analytic parameters. Parameter Value Reference interval Glycaemia (mg/dL) 717 74–109 HbA1c (%) 13 4–6 pH 7.42 7

Open access

Ana Gonçalves Ferreira, Tiago Nunes da Silva, Sofia Alegria, Maria Carlos Cordeiro and Jorge Portugal

0.4 mg twice daily. Subsequent 24-h BP monitoring revealed high systolic BP, with a concomitant high diastolic BP, especially at night (average 24-h BP of 155/81 mmHg and nocturnal of 167/83 mmHg), so amlodipine was switched to nifedipine 30 mg